STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTCT
  4. [Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

PTC Therapeutics (PTCT) director granted RSUs and 3,475 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics director Stephanie Okey reported new equity awards. On January 2, 2026, she received 4,000 shares of common stock as restricted stock units at a grant price of $0, increasing her directly held common stock to 12,000 shares after the transaction.

The restricted stock units vest over one year, with five-twelfths of the underlying shares vesting on June 2, 2026 and the remaining seven-twelfths vesting on January 2, 2027. She was also granted a stock option for 3,475 shares of common stock at an exercise price of $76.74 per share and a grant price of $0, vesting in twelve equal monthly installments starting February 2, 2026. Following this grant, she directly holds 3,475 stock options.

Positive

  • None.

Negative

  • None.
Insider Okey Stephanie
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 3,475 $0.00 --
Grant/Award Common Stock 4,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 3,475 shares (Direct); Common Stock — 12,000 shares (Direct)
Footnotes (1)
  1. Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Okey Stephanie
(Last) (First) (Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE
(Street)
WARREN NJ 07059
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/02/2026 A 4,000(1) A $0 12,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $76.74 01/02/2026 A 3,475 (2) 01/01/2036 Common Stock 3,475 $0 3,475 D
Explanation of Responses:
1. Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
2. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
/s/ Avraham S. Adler, Attorney-in-Fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PTC Therapeutics (PTCT) report for Stephanie Okey?

The filing reports that director Stephanie Okey received 4,000 shares of PTC Therapeutics common stock as restricted stock units and a stock option for 3,475 shares on January 2, 2026, both granted at a price of $0 per share.

How do Stephanie Okey’s restricted stock units at PTC Therapeutics (PTCT) vest?

The 4,000 restricted stock units granted on January 2, 2026 vest over one year: five-twelfths of the underlying shares vest on June 2, 2026, and the remaining seven-twelfths vest on January 2, 2027.

What are the key terms of Stephanie Okey’s stock option grant at PTC Therapeutics (PTCT)?

The stock option covers 3,475 shares of common stock with an exercise price of $76.74 per share. It was granted on January 2, 2026 and vests over one year in twelve equal monthly installments starting on February 2, 2026.

How many PTC Therapeutics shares does Stephanie Okey own after this Form 4 transaction?

After the reported transaction, Stephanie Okey directly beneficially owns 12,000 shares of PTC Therapeutics common stock and 3,475 stock options to buy additional shares.

What role does Stephanie Okey have at PTC Therapeutics (PTCT) according to the Form 4?

The Form 4 identifies Stephanie Okey as a director of PTC Therapeutics, with the form filed for one reporting person.

Were the equity awards to Stephanie Okey reported as direct or indirect ownership in PTC Therapeutics (PTCT)?

Both the 4,000 restricted stock units (reported as common stock) and the 3,475 stock options are listed as direct (D) ownership in the filing, with no separate entity named for indirect ownership.